9 results about "Aucubin" patented technology

The present invention provides a traditional Chinese medicine composition for clearing heat, removing blood stasis, stopping bleeding and regulating menstruation, and a preparation method thereof, relating to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition of the present invention comprises the following components: catalpol, aucubin, β-sitosterol, emodin, chrysophanol, sanguisorba officinalis extract, Panax notoginseng saponins, septamine, cuttlefish scaly, rubiacin, typhaneuroside, and p-coumaric acid; the components synergistically work together to significantly reduce plasma prothrombin time and plasma recalcification time, and significantly reduce the whole blood viscosity, plasma viscosity, and hematocrit of rats with blood stasis syndrome. The traditional Chinese medicine composition of the present invention is used in the preparation of drugs for menstrual disorders or menstrual bleeding and metrorrhagia, and has a significant therapeutic effect on irregular menstruation, excessive menstrual bleeding, or metrorrhagia.

The present invention discloses use of a male flower extract of Eucommia ulmoides Oliver in preparation of a food or a medicament for resisting muscle aging, belonging to the technical field of plant extracts. A main active ingredient of the male flower extract of Eucommia ulmoides Oliver is iridoids, and the composition of the iridoids includes aucubin, geniposide, geniposidic acid and asperuloside. The present invention reports for the first time that the male flower extract of Eucommia ulmoides Oliver and the iridoids contained therein have mitophagy activation activity and maintain normal mitochondrial function by effectively stimulating mitophagy. The extract has a relatively strong ability to prevent or alleviate aging-related muscle hypofunction, and has great application prospects in food, pharmaceutical and other fields.

The invention discloses application of aucubin in reducing fat deposition, and belongs to the field of biotechnology and animal husbandry application. The new application refers to application of aucubin in preparation of a composition for reducing fat deposition of non-human mammals. In particular, the composition can be used to induce and establish a standardized low fat deposition animal model or state, preferably a high fat diet induced obese mouse model (intragastric dose of 30 mg / kg body weight per day). In addition, the composition can also be used as a feed additive for non-human mammals. The aucubin is developed into a tool for constructing a standardized metabolism scientific research model for the first time, a brand new application scheme is provided for the aucubin as a safe and effective fat deposition regulating agent in livestock production, and the aucubin has important scientific research and industrial value.

The invention discloses preparation of a folium cortex eucommiae extract and application of the folium cortex eucommiae extract in improvement of age-related macular degeneration, and belongs to the technical field of traditional Chinese medicine extraction. The technical problem to be solved is how to prepare the folium cortex eucommiae extract which is higher in content of chlorogenic acid, cryptochlorogenic acid, neochlorogenic acid, aucubin and geniposidic acid and has a better anti-age-related macular degeneration effect. According to the technical scheme, the folium cortex eucommiae extract is characterized in that the content of chlorogenic acid is 50-100 mg / g, the content of cryptochlorogenic acid is 40-60 mg / g, the content of neochlorogenic acid is 35-55 mg / g, the content of aucubin is 56-79 mg / g, and the content of geniposidic acid is 65-105 mg / g. The folium cortex eucommiae extract obtained by the method can better retain effective components in the folium cortex eucommiae extract, and a better anti-age-related macular degeneration effect is embodied.

The invention discloses a comprehensive evaluation method for the quality of eucommia male flowers and application, belongs to the technical field of quality detection of traditional Chinese medicinal materials, and aims to solve the technical problems of single evaluation means, low efficiency and disjunction of quality and efficacy of the traditional eucommia male flowers. The method comprises the following five core steps: preparing a test solution, constructing and evaluating an UPLC (Ultra Performance Liquid Chromatography) exclusive fingerprint spectrum, quantifying HPLC (High Performance Liquid Chromatography) multi-index functional components, determining the functionality of total polyphenols and total flavonoids and carrying out three-dimensional synergistic judgment. Efficient separation of 19 common characteristic peaks is achieved through customized UPLC chromatographic conditions, the relative retention time range of the characteristic peaks is limited by taking chlorogenic acid as a reference peak, and content limits of four core active ingredients such as aucubin and the like, total polyphenol and total flavone are set based on an efficacy threshold value; and meanwhile, a plurality of groups of defensive experiments are additionally arranged to verify system collaboration, industrial practicability and efficacy relevance. According to the method, three-dimensional management and control of overall qualification, precise quantification and efficacy association of the eucommia ulmoides male flowers are achieved, the UPLC fingerprint detection efficiency is improved by 61% compared with a traditional HPLC method, the authenticity identification accuracy rate reaches 100%, the method is suitable for large-scale application of the whole industrial chain, and a scientific and feasible technical scheme is provided for standardized management and control of the quality of the eucommia ulmoides male flowers.

The invention discloses an application of aucubin in preparation of a medicine for improving ischemia-reperfusion pan apoptosis of lower limbs, on one hand, an in-vitro cell experiment shows that the aucubin treatment can improve the cell viability of a mouse primary gastrocnemius muscle pan apoptosis model and reduce the cell apoptosis, so that the scratch healing rate is improved; meanwhile, the expression of related death proteins of a pan-apoptotic cell model can be reduced; on the other hand, animal in-vivo experiments show that aucubin can regulate a TNF-NFKB pathway through negative feedback and inhibit polarization of M1 inflammatory macrophages, so that expression of lower limb ischemia reperfusion pan-apoptosis protein is reduced, and the effect of improving pan-apoptosis caused by lower limb ischemia reperfusion is achieved.

The present application provides the use of aucubin or the combination of aucubin and ACA in the preparation of a medicament for treating ischemic brain injury, in particular acute cerebral ischemia-reperfusion injury. The present application first discovers that aucubin or the combination of aucubin and ACA can increase the blood flow of the ischemic side after ischemic brain injury in mice; significantly reduce the cerebral infarction volume; improve the cognitive and motor function of mice after ischemic brain injury; reduce the degree of injury caused by cerebral ischemia, significantly improve the degree of neuronal necrosis of brain tissue after ischemia; significantly increase the survival rate of HT22 cells after oxygen-glucose deprivation and reperfusion injury, reduce intracellular Ca 2+ fluorescence intensity, and inhibit cell apoptosis.

The invention relates to the technical field of biological medicine, in particular to application of rhamnoside B in preparation of a medicine for treating breast cancer. The rhamnoside B (GB) plays an anti-tumor role by targeting mitochondria, the mechanisms comprise induction of mitochondrial dysfunction, interference of energy metabolism, induction of oxidative stress, activation of apoptosis pathway and the like, and an important basis is provided for development of novel mitochondrial targeting anti-breast cancer drugs.

The invention relates to a cytochrome P450 gene RcCYP72H7 participating in catalpol synthesis as well as a coding product and application of the cytochrome P450 gene RcCYP72H7. According to the invention, a cytochrome P450 gene RcCYP72H7 sequence participating in catalpol synthesis is cloned from rehmannia root, and an amino acid sequence coded by the cytochrome P450 gene RcCYP72H7 sequence is speculated and obtained. The gene can instantaneously express RcCYP72H7 in the leaf of nicotiana benthamiana to catalyze the synthesis of catalpol from auculia aucuba, and the catalpol content in the leaf of rehmannia temminea can be obviously increased. The key effect of the cytochrome P450 enzyme RcCYP72H7 in catalpol epoxidation synthesis of aucubin is cloned and verified for the first time, catalpol is heterologous synthesized and produced through synthetic biology or metabolic engineering technology, and the method can be used for improving the quality of rehmannia root.